About 8% of men, or roughly 1 in 12, are colorblind. That makes color vision deficiency one of the most common genetic conditions in the world, and it overwhelmingly affects males. For comparison, only about 1 in 200 women have it.
Why the Number Is So Much Higher in Men
The genes responsible for detecting red and green light sit on the X chromosome. Men have only one X chromosome (paired with a Y), so a single faulty copy of either gene is enough to cause color blindness. Women have two X chromosomes, which means a working copy on the second X can compensate for a defective one on the first. For a woman to be colorblind, she would need the same genetic variant on both of her X chromosomes, which is far less likely.
This inheritance pattern is called X-linked recessive. It’s the same reason hemophilia and certain types of muscular dystrophy also show up more frequently in men. A colorblind father will pass his X chromosome to all of his daughters (making them carriers) but none of his sons. A carrier mother has a 50% chance of passing the gene to each child, which means roughly half her sons will be colorblind and half her daughters will be carriers.
Rates Vary by Ethnicity
The 8% figure is a global average, but prevalence differs across ethnic groups. A large study of over 4,000 preschool-age boys in California found notable variation:
- Caucasian boys: 5.6%
- Asian boys: 3.1%
- Hispanic boys: 2.6%
- African American boys: 1.4%
These numbers are lower than the commonly cited 8% because they reflect preschool-age children tested in a specific region. Adult prevalence rates for men of Northern European descent tend to cluster closer to 8%, while rates in populations of African and East Asian descent are generally lower. The reasons likely involve differences in the frequency of the relevant gene variants across populations, shaped over thousands of years.
What “Colorblind” Actually Means
Most colorblind men are not seeing the world in black and white. The vast majority have red-green color deficiency, meaning they have trouble distinguishing between reds, greens, browns, and oranges. Within that category, there’s a spectrum. Some men have a mild shift in how they perceive color, while others can barely tell red from green at all.
The condition breaks down into a few types based on severity. Among boys and young men studied globally, about 1.6% have dichromacy, where one of the three types of color-detecting cells in the eye is completely nonfunctional. Another 1.2% have anomalous trichromacy, a milder form where all three cell types work but one responds to a shifted range of wavelengths. And about 0.4% have monochromacy, the rarest and most severe form, where color perception is extremely limited or absent entirely.
Blue-yellow color blindness also exists but is much rarer and is not linked to the X chromosome, so it affects men and women at similar rates.
How Color Blindness Is Diagnosed
The standard screening tool is the Ishihara test, a series of circular plates filled with colored dots that form numbers or patterns. People with normal color vision can read the numbers easily, while those with a deficiency see a different number or nothing at all. The test has been in clinical use for over a century and remains highly reliable, with sensitivity above 96% for detecting color vision problems.
Digital versions of the test are now available online and through apps. A recent study of 330 patients found that one web-based tool matched the Ishihara test’s results about 88% of the time. These can be useful for a quick check, but an in-person test with controlled lighting gives the most accurate result.
Many men don’t realize they’re colorblind until they’re tested in school or at a workplace screening. Because they’ve never seen colors differently, they have no frame of reference for what they’re missing. It’s common for someone to reach adulthood before learning that the greens and browns they see look distinctly different to everyone else.
Career and Daily Life Impact
Color blindness is rarely a medical emergency, but it can create real barriers. A number of professions restrict or disqualify people with color vision deficiency because of safety concerns. Pilots, electricians, firefighters, military and naval personnel, police officers, and commercial drivers all face color vision requirements in many countries. The issue is practical: misreading a signal light, confusing color-coded wires, or missing a visual warning can have serious consequences.
Design-related careers like graphic design, interior design, and fashion also present challenges, though they don’t carry formal restrictions. Some colorblind designers find workarounds using digital tools that label colors by name or hex code, but the limitation is real.
In everyday life, the effects range from minor inconveniences to genuine frustration. Picking out ripe fruit, reading color-coded charts, matching clothes, interpreting maps, and playing certain video games can all be harder. Many colorblind men develop compensating strategies without thinking about it, relying on brightness, position, or context clues instead of color. For example, knowing the top light on a traffic signal is red and the bottom is green, rather than distinguishing the colors themselves.
Treatment Options
There is currently no cure for inherited color blindness. Tinted glasses and contact lenses marketed to colorblind people can enhance contrast between certain colors, and some users report a dramatic improvement in their experience. However, these lenses don’t restore normal color vision. They work by filtering specific wavelengths to make reds and greens more distinguishable, which helps in some situations but not all.
Gene therapy is being explored in clinical trials, with research that began in 2016 focused initially on achromatopsia, the most severe form involving near-total color blindness and significant vision loss. These trials are ongoing. If successful, they could eventually open the door to gene-based treatments for the more common red-green deficiency, but that possibility remains years away from clinical availability.